SMT201700276T1 - Composti e composizioni quali modulatori dell’attività di tlr - Google Patents

Composti e composizioni quali modulatori dell’attività di tlr

Info

Publication number
SMT201700276T1
SMT201700276T1 SM20170276T SMT201700276T SMT201700276T1 SM T201700276 T1 SMT201700276 T1 SM T201700276T1 SM 20170276 T SM20170276 T SM 20170276T SM T201700276 T SMT201700276 T SM T201700276T SM T201700276 T1 SMT201700276 T1 SM T201700276T1
Authority
SM
San Marino
Prior art keywords
compositions
compounds
activity modulators
tlr activity
tlr
Prior art date
Application number
SM20170276T
Other languages
English (en)
Italian (it)
Inventor
Manmohan Singh
Alex Cortez
Yongkai Li
David Skibinski
Tom Yao-Hsiang Wu
Kathy Yue
Xiaoyue Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201700276(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMT201700276T1 publication Critical patent/SMT201700276T1/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM20170276T 2009-09-02 2010-09-01 Composti e composizioni quali modulatori dell’attività di tlr SMT201700276T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23921709P 2009-09-02 2009-09-02
EP10807754.6A EP2473508B1 (en) 2009-09-02 2010-09-01 Compounds and compositions as tlr activity modulators
PCT/US2010/047587 WO2011049677A1 (en) 2009-09-02 2010-09-01 Compounds and compositions as tlr activity modulators

Publications (1)

Publication Number Publication Date
SMT201700276T1 true SMT201700276T1 (it) 2017-07-18

Family

ID=43625759

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20170276T SMT201700276T1 (it) 2009-09-02 2010-09-01 Composti e composizioni quali modulatori dell’attività di tlr

Country Status (27)

Country Link
US (2) US9045470B2 (OSRAM)
EP (1) EP2473508B1 (OSRAM)
JP (1) JP5525614B2 (OSRAM)
CN (1) CN102712636B (OSRAM)
AR (1) AR078153A1 (OSRAM)
AU (1) AU2010308524B2 (OSRAM)
BR (1) BR112012004696B8 (OSRAM)
CA (1) CA2772657C (OSRAM)
CL (1) CL2012000535A1 (OSRAM)
CY (1) CY1119618T1 (OSRAM)
DK (1) DK2473508T3 (OSRAM)
EA (1) EA020962B1 (OSRAM)
ES (1) ES2627669T3 (OSRAM)
HR (1) HRP20170707T1 (OSRAM)
HU (1) HUE032323T2 (OSRAM)
IN (1) IN2012DN02736A (OSRAM)
JO (1) JO3257B1 (OSRAM)
LT (1) LT2473508T (OSRAM)
MX (1) MX2012002654A (OSRAM)
PE (1) PE20121156A1 (OSRAM)
PL (1) PL2473508T3 (OSRAM)
PT (1) PT2473508T (OSRAM)
SI (1) SI2473508T1 (OSRAM)
SM (1) SMT201700276T1 (OSRAM)
TW (1) TWI445708B (OSRAM)
UY (1) UY32874A (OSRAM)
WO (1) WO2011049677A1 (OSRAM)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125942A1 (en) * 2011-03-16 2012-09-20 University Of Medicine And Dentistry Of New Jersey Combination therapy with leukotoxin
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
US10149889B2 (en) 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Tlr活性モジュレーターを含む免疫原性組成物
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
EP2402028A1 (en) * 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus vaccines for preventing and treating type 1 diabetes (II)
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
PT3981427T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
EP2729165B1 (en) * 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
MX2014002363A (es) * 2011-09-01 2014-04-14 Novartis Ag Formulaciones de antigenos de staphylococcus aureus con adyuvante.
FI123955B (en) * 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
EP2822589A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of rabies virus immunogens
CN104519910B (zh) * 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
CN104203946B (zh) * 2012-03-07 2017-03-22 诺华股份有限公司 免疫上有用的精氨酸盐
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2877492A1 (en) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014033192A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
CN103845731B (zh) * 2012-12-05 2015-12-02 复旦大学 抗st2/il-1r4抗体在制备防治瘙痒药物中的应用
EP2943221A1 (en) * 2013-01-10 2015-11-18 Novartis AG Influenza virus immunogenic compositions and uses thereof
ES2670863T3 (es) * 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
AU2014264501A1 (en) 2013-05-10 2015-12-10 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
MA40238A (fr) 2014-07-11 2017-05-17 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
BR102015023450A2 (pt) 2014-09-16 2016-04-12 Gilead Sciences Inc formas sólidas de um modulador do receptor semelhante a toll
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
JP7046016B2 (ja) 2016-06-30 2022-04-01 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ Herv-e反応性t細胞受容体および使用方法
JP7029400B2 (ja) * 2016-09-09 2022-03-03 武田薬品工業株式会社 環状化合物
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
US12239702B2 (en) 2017-12-04 2025-03-04 Intervet Inc. Vaccination with replicon particles and oil adjuvant
JP7351859B2 (ja) * 2018-06-04 2023-09-27 アプロス セラピューティクス, インコーポレイテッド Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
MX2021009496A (es) 2019-02-08 2021-09-08 Progeneer Inc Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
US12479817B2 (en) 2019-02-15 2025-11-25 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020251582A1 (en) * 2019-04-05 2021-12-02 Sumitomo Pharma Co., Ltd. Water soluble adjuvant
CN114096560B (zh) * 2019-07-03 2025-06-13 默克专利股份公司 糖型纯化
JP7590400B2 (ja) * 2019-07-03 2024-11-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体薬物コンジュゲートの精製
JP2023506958A (ja) 2019-12-20 2023-02-20 ノバルティス アーゲー 骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗pd-1抗体スパルタリズマブを伴うかまたは伴わない抗tim-3抗体mbg453および抗tgf-ベータ抗体nis793の組合せ
JP2023507322A (ja) 2019-12-20 2023-02-22 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なToll様受容体(「TLR」)アゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
EP4115901A4 (en) 2020-03-02 2024-04-10 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN116262750A (zh) * 2021-12-15 2023-06-16 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法和用途
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024255837A1 (zh) * 2023-06-15 2024-12-19 石药集团中奇制药技术(石家庄)有限公司 一种enpp1抑制剂的晶型

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
JP2000511769A (ja) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション 新規化合物
JP2000512487A (ja) 1996-05-14 2000-09-26 スミスクライン・ビーチャム・コーポレイション 新規化合物
EP0942983B2 (en) 1996-10-31 2014-09-10 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
CA2300854C (en) 1997-08-21 2011-04-05 Peter Andre Van Der Ley Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
JPH1180156A (ja) * 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
EP2319931A1 (en) 1997-11-26 2011-05-11 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
EP1073450A4 (en) 1998-04-23 2003-04-23 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C (PSPC), EPITOPIC REGIONS, SELECTION OF CORRESPONDING STRES AND USES
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
WO2000006738A2 (en) 1998-07-27 2000-02-10 Microbial Technics Limited NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE)
ATE361365T1 (de) 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
BR9913340A (pt) 1998-08-31 2001-11-06 Inhibitex Inc Composição, vacina, e, processos de gerar uma resposta imune, e de inibir a colonização microbiana em um animal
WO2000012689A1 (en) 1998-08-31 2000-03-09 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
PT1140157E (pt) 1998-12-21 2009-05-06 Medimmune Inc Proteínas de streptococcus pneumoniae e fragmentos imunogénicos para vacinas
CN100379758C (zh) 1999-03-26 2008-04-09 科特克斯(Om)有限公司 肺炎链球菌抗原
HK1043943A1 (zh) 1999-06-10 2002-10-04 Medimmune, Inc. 肺炎链球菌蛋白质和疫苗
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
DE60144353D1 (de) 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybride Expression Neisserscher Proteine
CA2404260A1 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
WO2001081380A2 (en) 2000-04-27 2001-11-01 Medimmune, Inc. Immunogenic pneumococcal protein and vaccine compositions thereof
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6495079B1 (en) 2000-06-28 2002-12-17 Prisma Fibers, Inc. Process to prepare polymeric fibers with improved color and appearance
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
AU2001287645A1 (en) 2000-07-20 2002-02-05 Hansa Medical Ab Fh-binding protein of streptococcus pneumiae
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1330473A2 (en) 2000-10-26 2003-07-30 Imperial College Innovations Limited Streptococcal genes
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
EP1399181B1 (en) 2001-05-18 2012-05-09 The Government of the USA, as represented by the Secretary, Dept. of Health and Human Services, Centers for Disease Control and Prevention Peptide vaccines against group a streptococci
MXPA03011701A (es) 2001-06-15 2004-12-06 Nhibitex Inc Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus.
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP1412379B1 (en) 2001-08-02 2012-01-25 The University Of Sheffield Vaccine
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Chlamydiatrachomatisに対する免疫化
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
EP2275128B1 (en) 2002-04-02 2013-10-16 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
KR20050010040A (ko) 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
AU2003260357B2 (en) 2002-08-02 2009-10-29 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004041157A2 (en) 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
HUE047780T2 (hu) 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2522379C (en) 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
CA2522238A1 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
US20100255002A1 (en) 2003-06-26 2010-10-07 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
WO2005032582A2 (en) 2003-07-31 2005-04-14 Chiron Corporation Immunogenic compositions for streptococcus pyogenes
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
JP4993750B2 (ja) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、gna1870を基にした小胞ワクチン
KR20080114683A (ko) 2005-12-27 2008-12-31 오베테크, 엘엘씨 질병에 대한 바이오마커로서의 지방생성 아데노바이러스
EP1998800A2 (en) 2006-01-18 2008-12-10 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US20080031877A1 (en) 2006-02-17 2008-02-07 Antonello Covacci Purification of bacterial antigens
ATE539079T1 (de) * 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
PT2268618E (pt) * 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
AU2010258677B2 (en) * 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
CN102760226B (zh) * 2011-04-29 2015-07-01 贵州师范大学 一种基于实心正方形的试卷客观题答题卡定位方法

Also Published As

Publication number Publication date
BR112012004696A2 (pt) 2017-05-23
IN2012DN02736A (OSRAM) 2015-09-11
AU2010308524B2 (en) 2014-03-20
AR078153A1 (es) 2011-10-19
DK2473508T3 (en) 2017-06-06
HUE032323T2 (en) 2017-09-28
CL2012000535A1 (es) 2012-08-17
TW201113281A (en) 2011-04-16
ES2627669T3 (es) 2017-07-31
US20150225432A1 (en) 2015-08-13
LT2473508T (lt) 2017-06-12
WO2011049677A1 (en) 2011-04-28
CA2772657A1 (en) 2011-04-28
CN102712636A (zh) 2012-10-03
SI2473508T1 (sl) 2017-07-31
CY1119618T1 (el) 2018-04-04
HRP20170707T1 (hr) 2017-07-14
JP2013503884A (ja) 2013-02-04
EP2473508B1 (en) 2017-03-08
EP2473508A1 (en) 2012-07-11
CA2772657C (en) 2015-11-24
US20110053893A1 (en) 2011-03-03
EA020962B1 (ru) 2015-03-31
PL2473508T3 (pl) 2017-08-31
JO3257B1 (ar) 2018-09-16
CN102712636B (zh) 2014-11-05
US9045470B2 (en) 2015-06-02
TWI445708B (zh) 2014-07-21
PE20121156A1 (es) 2012-08-23
BR112012004696B8 (pt) 2021-05-25
PT2473508T (pt) 2017-05-29
UY32874A (es) 2011-04-29
BR112012004696B1 (pt) 2021-01-05
MX2012002654A (es) 2012-03-26
AU2010308524A1 (en) 2012-04-19
EA201200406A1 (ru) 2012-09-28
JP5525614B2 (ja) 2014-06-18

Similar Documents

Publication Publication Date Title
PL2473508T3 (pl) Związki i kompozycje jako modulatory aktywności TLR
ZA201006473B (en) Compounds and compositions as tlr activity modulators
AP3106A (en) Antiparisitic dihydroazole compounds and compositions comprising same
SG10201403696UA (en) Therapeutic compounds and compositions
SI3812360T1 (sl) Monoklorotrifluoropropenske spojine in sestavki ter postopki, ki jih uporabljajo
PL2336285T3 (pl) Kompozycja zawierająca mikrokapsułki
IL217955A (en) Pesticides and pesticides containing them
GB201002983D0 (en) Nutritinal composition
GB201021186D0 (en) Composition
ZA201209259B (en) Uses and compositions
GB201019297D0 (en) Improved compositions
IL214660A0 (en) Agricultural composition
ZA201201645B (en) Cosmetic composition
GB0920879D0 (en) Cosmetic composition
GB201010374D0 (en) Disinfectant composition
IL221959A (en) Profinilaminond trans-skin preparations
GB201017048D0 (en) Composition
GB201016970D0 (en) Composition
GB201005927D0 (en) Improved composition
GB201118532D0 (en) Absorbent composition
GB201004717D0 (en) Composition
GB201006175D0 (en) Composition
GB201006012D0 (en) Composition
GB201002356D0 (en) Composition
GB201005275D0 (en) Agents to prevent binding